VIENNA, Va., Sept. 26 /PRNewswire/ -- CEL-SCI CORPORATION (Amex: CVM),
a drug development company with its lead cancer product cleared for a Phase
III trial, today announced that Chief Executive Officer, Geert Kersten is
featured in an interview with the Wall Street Reporter. Interested parties
may go to http://www.wallstreetreporter.com to access the interview. The
Wall Street Reporter is a premier information source for professional
investors seeking successful new investment ideas.
CEL-SCI Corporation is developing new immune system based treatments
for cancer and infectious diseases. The Company has operations in Vienna,
Virginia and Baltimore, Maryland. The Company's lead product Multikine(R)
is cleared to enter global Phase III clinical trials in advanced primary
head and neck cancer patients. CEL-SCI's other products, which are
currently in pre- clinical stage and are funded with U.S. government
support, have shown protection against a number of diseases in animal tests
and are being tested against diseases associated with bio-defense and avian
flu.
SOURCE CEL-SCI Corporation
 back to top
Related links:
http://www.cel-sci.com
http://www.wallstreetreporter.com
CONTACT:
Gavin de Windt of CEL-SCI Corporation,
+1-703-506-9460
|
